期刊
JOURNAL OF HUMAN HYPERTENSION
卷 35, 期 1, 页码 12-25出版社
SPRINGERNATURE
DOI: 10.1038/s41371-020-00393-4
关键词
-
资金
- Hellenic Society for Medical Education
- Astra Zeneca
Chronic kidney disease is a major public health issue and strict blood pressure control and renin-angiotensin system (RAS) blocker use are essential in its treatment. SGLT-2 inhibitors have shown promising nephroprotective properties in patients with type 2 diabetes mellitus, reducing albuminuria and the risk of hard renal outcomes.
Chronic kidney disease (CKD) is a major public health issue and an independent risk factor for cardiovascular and all-cause mortality. Diabetic kidney disease develops in 30-50% of diabetic patients and it is the leading cause of end-stage renal disease in the Western world. Strict blood pressure control and renin-angiotensin system (RAS) blocker use are the cornerstones of CKD treatment; however, their application in everyday clinical practice is not always ideal and in many patients CKD progression still occurs. Accumulated evidence in the past few years clearly suggests that sodium-glucose co-transporter-2 (SGLT-2) inhibitors present potent nephroprotective properties. In clinical trials in patients with type 2 diabetes mellitus, these agents were shown to reduce albuminuria and proteinuria by 30-50% and the incidence of composite hard renal outcomes by 40-50%. Furthermore, their mechanism of action appears rather solid, as they interfere with the major mechanism of proteinuric CKD progression, i.e., glomerular hypertension and hyperfiltration. The present review summarizes the current evidence from human trials on the effects of SGLT-2 inhibitors on nephroprotection and discusses their position in everyday clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据